article
Expert view: Preparing drug discovery for smart screening era
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
List view / Grid view
AstraZeneca
news
Charles River Laboratories makes investments in high-throughput screening infrastructure
Signs collaboration agreement with AstraZeneca to offer state-of-the-art technology to clients.
news
Industry-academic collaboration results in improved understanding of cancer cell regulation
A team of researchers from the University of Liverpool and AstraZeneca has made an important contribution to our understanding of cancer cell regulation, holding promise for improved future cancer treatment.
article
Artificial intelligence in drug discovery: how long before we see the real impact?
A new race is well underway involving big pharma and big data companies to see who can most effectively mine the new massive data using artificial intelligence (AI). The aim: reducing costs by using targeted in silico analysis, reducing in vitro and in vivo screening, and reviewing huge quantities of…
news
Richard Goodwin joins DTR Advisory Board
Dr Goodwin is the latest top-level scientist to join DTR's advisory board
editorial-board
Richard Goodwin
11 October 2017 | By
Principal Scientist, Drug Safety and Metabolism at AstraZeneca
article
Mass spectrometry imaging in drug discovery
Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.
article
Imaging In-Depth Focus 2017
This In-Depth Focus explores current uses and future development in mass spectrometry imaging for bringing new drugs to market...
news
MRC forges two new deals with industry to speed drug discovery
The Medical Research Council has formed partnerships with UCB and AstraZeneca, the deals will help speed translation of discovery research into potential therapies...
news
Imfinzi wins breakthrough therapy designation
AstraZeneca and MedImmune, have today announced that the US Food and Drug Administration has granted breakthrough therapy designation for Imfinzi for the treatment of patients with locally-advanced, unresectable non-small cell lung cancer...
news
Flexible new method for early cancer diagnosis
Investments are now being made to roll out this innovation across healthcare and broaden the scope of the research in this field.
news
Scandinavian programme launched to produce all human secreted proteins
A new research programme has been launched to produce all the human secreted proteins in mammalian cell factories. The programme aims to facilitate studies of this important class of proteins, which are involved in many human diseases.
news
Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
news
Big pharma establishes new industry standards group
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
news
AstraZeneca provide insight into biomarkers and personalised treatment at Asthma & COPD 2017
SMi’s 13th annual Asthma & COPD conference returns to London on the 29 and 30 March 2017...